The Union Ministry of Health and Family Welfare has proposed a dedicated licensing framework for the wholesale trade of bulk drugs—covering both active and inactive pharmaceutical substances—to strengthen regulatory oversight, curb antimicrobial resistance, and tighten accountability across India’s pharmaceutical supply chain.
Notified through Draft Gazette Notification G.S.R. No. 987 (E), the proposed amendments to the Drugs Rules, 1945, seek to replace the current common wholesale licence—which jointly covers finished formulations and bulk drugs—with a separate application form (Form 19-BC) and licence form (Form 20-BC) exclusively for bulk drug wholesalers.
Key Provisions: Competent Supervision, NDPS Tracking & AMR Control
Cleared earlier by the Drugs Consultative Committee (DCC) at its 67th meeting on November 17, 2025, and the Drugs Technical Advisory Board (DTAB) at its 93rd meeting on February 16, 2026, the draft framework introduces strict operational safeguards:
- Category-Specific Mapping & NDPS Oversight: The new bulk-drug licence will explicitly record the categories of bulk substances handled by a wholesaler, including substances regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
- Mandatory Competent Person Supervision: All wholesale transactions of bulk drugs must take place under the personal supervision of a competent person, ensuring tighter accountability in handling and distribution.
- Curbing Antimicrobial Resistance (AMR): According to the ministry, separating bulk drug wholesale licensing will improve enforcement against unauthorized diversion of raw antibiotic ingredients—strengthening efforts against antimicrobial resistance—while enhancing tracking of NDPS substances.
12-Month Compliance Window & 30-Day Public Consultation
To ensure a smooth transition for existing pharma distributors, the Health Ministry clarified that the revised rules will apply to current licence holders only upon the expiry of their existing retention period or 12 months after final publication of the amended rules, whichever is later.
Stakeholders, industry bodies, and members of the public have been invited to submit objections or suggestions to the Under Secretary (Drugs), Ministry of Health and Family Welfare (or via email at drugsdiv-mohfw@gov.in) within 30 days from the date copies of the draft gazette notification are made available.
















